의약품부작용보고원시자료(KIDS-KD)를 활용한 baricitinib 및 tocilizumab의 이상사례 분석 및 실마리정보 검색
Adverse Events Analysis and Signal Detection of Baricitinib and Tocilizumab, using KIDS-KD: Focusing on the Adverse Events that may Affect COVID-19
- 대한약학회
- 약학회지
- 제66권 제2호(2022년)
- : KCI등재
- 2022.04
- 49 - 57 (9 pages)
Research shows that some severe COVID-19 patients exhibit an excessive inflammatory response with persistent fever; therefore, the drugs that inhibit one or more components of the pro-inflammatory cascade are administered to prevent the worsening of the condition of such patients. According to current updated COVID-19 guidelines, baricitinib and tocilizumab could be administered in COVID-19 patients in certain circumstances. To confirm the safety of these drugs, we analyzed the frequency of the adverse events and detected signals using KIDS-KD. We defined the signals by proportional reporting ratios (PRR), reporting odds ratios (ROR), and information components (IC). “Respiratory system disease” was frequently reported, with both baricitinib (17 cases, 15.0%) and tocilizumab (40 cases, 10.6%). It was also detected as a signal with baricitinib but not with tocilizumab. As the symptoms of COVID-19 are mainly related to the respiratory system, close monitoring is necessary for these patients. In relation to the risk of infection with tocilizumab, leucopenia (18 cases, 4.7%) and granulocytopenia (7 cases, 1.8%) were reported, and leucopenia was detected as a signal. With baricitinib, pyelonephritis was detected as a signal; however, no prior research that supports this finding exists. We expect this study to provide basic data on the safety of administering baricitinib and tocilizumab for COVID-19 patients in certain circumstances.
서론(Introduction)
방법(Methods)
결과(Results)
고찰(Discussion)
결론(Conclusion)
Conflict of Interest
References